AI-prediction

AI-prediction Overview

Antibody-dependent cellular cytotoxicity (ADCC) is one major mode of action of therapeutic monoclonal Abs (mAbs). The immune mechanism relies on mAb dual activity: the variable region ensures the specific recognition of an antigen expressed by a target cell, and the Fc in the constant region binds to Fc receptors (FcRs) at the surface of effector cells. Once the effector cells are activated, they will release cytotoxic granules and kill the target cells.

Applications

Measurement of LDH-release in PBMC mediated target cell killing system

Measurement of CD16 signal activation in Jurkat-NFAT-CD16 reporter coculture system

Specifications

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included.

Turn-Around Time: 2 – 3 weeks Timeline & pricing may vary depending on custom assay specifications.

Case Study

Overview

ADCP: Similar to ADCC, another major Fc effector function is antibody-dependent cellular phagocytosis (ADCP). This immune mechanism relies on antibodies’ ability to recognizes target cells and activate the FcγRs on the surface of macrophages to induce phagocytosis, resulting in internalization and degradation of the target cell through phagosome acidification.

Applications

Measurement of LDH-release in PBMC mediated target cell killing system

Measurement of CD16 signal activation in Jurkat-NFAT-CD16 reporter coculture system

Specifications

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included.

Turn-Around Time: 2 – 3 weeks Timeline & pricing may vary depending on custom assay specifications.

Case Study

Overview

CDC: Complement-dependent cytotoxicity (CDC) is a potent effector mechanism of IgG and IgM antibodies. It is initiated when the protein C1q complex binds to the antibody-antigen complex and triggers the classical complement pathway. It is one important mechanism of action by which therapeutic antibodies and antibody fragments can achieve the antitumor effect.

Specifications

Assays are performed using a 96-well format. Each data point is tested in triplicate, and appropriate assay controls are included.

Turn-Around Time: 2 – 3 weeks Timeline & pricing may vary depending on custom assay specifications.

All Drug Combination Services

In vivo combination studies offer insight into drug interactions facilitating profound insight into therapeutic dynamics, paving the way for enhanced medical research, optimizing patient care, and driving informed decision-making processes.
In vitro combination studies provide an in-depth analysis of cellular interactions. They illuminate drug synergy or antagonism, serving as an essential tool for crafting enhanced therapeutic strategies and optimized drug formulations.
Our AI-prediction platform excels in predicting drug responses, interactions, and potential outcomes. Utilizing cutting-edge technology, we accelerate drug development, ensuring a more efficient and effective approach to the development of therapeutic strategies.